A Phase 3, Open-label Interventional Study of an Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, BIVV001, in Patients With Severe Hemophilia A (XTEND-1)
Condition: Factor VIII Deficiency Intervention: Drug: BIVV001 Sponsor: Sanofi Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials